Intended for healthcare professionals


Cystic fibrosis drugs are rejected for NHS use in Scotland

BMJ 2019; 366 doi: (Published 13 August 2019) Cite this as: BMJ 2019;366:l5137
  1. Bryan Christie
  1. Edinburgh

Expensive drugs to treat cystic fibrosis have been rejected for use on the NHS in Scotland, but discussions continue with the manufacturer to try to make them available.

The Scottish Medicines Consortium, which advises NHS Scotland on the use of new drugs, said that there remained “significant uncertainty” over the overall health benefits of Orkambi (combination of lumacaftor and ivacaftor) and Symkevi (tezacaftor and ivacaftor) in relation to their …

View Full Text

Log in

Log in through your institution


* For online subscription